Early research (Phase 1)Study completedNCT01021397
What this trial is testing
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Who this might be right for
Paramyxoviridae InfectionsVirus Diseases
National Institute of Allergy and Infectious Diseases (NIAID) 12